Influenza hemagglutinin peptide-MHC class II complex (HA-MHC II)

The Influenza hemagglutinin peptide-MHC class II complex is a specialized molecular assembly presented on the surface of professional antigen-presenting cells (APCs), such as dendritic cells and B cells (PubMed: 8114711). It consists of a processed peptide fragment from the influenza hemagglutinin (HA) protein, most notably the immunodominant HA 306-318 sequence, non-covalently bound within the peptide-binding groove of a Major Histocompatibility Complex (MHC) class II molecule, typically HLA-DR1 or HLA-DR4 (PDB: 1DLH). This complex is the fundamental unit recognized by the T-cell receptor (TCR) of CD4+ helper T cells, which is essential for initiating the adaptive immune response, including B-cell help for antibody production and cytokine secretion (Nature, 1994). In clinical research, this complex is a primary target for the development of universal influenza vaccines, such as M-001, which aim to provide broad protection by targeting conserved HA epitopes (Vaccines, 2020). Additionally, TCR-mimetic antibodies are being engineered to target these specific pMHC complexes for therapeutic and diagnostic applications in viral infections and potentially autoimmune conditions where HA-like peptides may play a role (Frontiers in Immunology, 2018). The stability and presentation of this complex are critical determinants of the magnitude and quality of the anti-viral immune response.

Other names

HA-peptide/MHC II complexHA306-318/HLA-DR complexHemagglutinin-MHC II complexpMHC II complexHA-pMHCIIHemagglutinin-derived peptide–MHC class II complexes

The complex acts as a ligand for the T-cell receptor (TCR) on CD4+ T lymphocytes; the specific recognition of the peptide-MHC interface by the TCR triggers intracellular signaling pathways (e.g., Lck, ZAP-70 activation) leading to T-cell proliferation, cytokine production, and orchestration of the adaptive immune response.